Adaptimmune Therapeutics (ADAP) Earnings Date, Estimates & Call Transcripts

$1.08
+0.07 (+6.93%)
(As of 10:58 AM ET)

Earnings Summary

Upcoming
Earnings Date
May. 10Estimated
Actual EPS
(Mar. 6)
-$0.24 Missed By -$0.12
Consensus EPS
(Mar. 6)
-$0.12
Skip Charts & View Estimated and Actual Earnings Data

ADAP Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

ADAP Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Adaptimmune Therapeutics Analyst EPS Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20241($0.12)($0.12)($0.12)
Q2 20241($0.13)($0.13)($0.13)
Q3 20241($0.12)($0.12)($0.12)
Q4 20241($0.11)($0.11)($0.11)
FY 20244($0.48)($0.48)($0.48)

ADAP Earnings Date and Information

Adaptimmune Therapeutics last released its earnings results on March 6th, 2024. The biotechnology company reported ($0.24) earnings per share for the quarter, missing analysts' consensus estimates of ($0.12) by $0.12. The firm had revenue of $0.23 million for the quarter, compared to analysts' expectations of $4.80 million. Adaptimmune Therapeutics has generated ($0.55) earnings per share over the last year (($0.55) diluted earnings per share). Earnings for Adaptimmune Therapeutics are expected to grow in the coming year, from ($0.49) to ($0.48) per share. Adaptimmune Therapeutics has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Friday, May 10th, 2024 based off prior year's report dates.

Adaptimmune Therapeutics Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript
5/10/2024
Estimated)
------- 
3/6/2024Q4 2023($0.12)($0.24)($0.12)($0.24)$4.80 million$0.23 million
11/8/2023Q3 2023($0.20)($0.20)-($0.20)$5.00 million$7.32 million
8/9/2023Q2 2023($0.17)($0.21)($0.04)($0.30)$5.00 million$5.13 million
5/12/2023Q1 2023($0.19)$0.01+$0.20$0.01$7.70 million$47.60 million
3/6/2023Q4 2022($0.25)($0.18)+$0.07($0.18)$7.50 million$11.03 million
11/8/2022Q3 2022($0.28)($0.24)+$0.04($0.24)$4.40 million$7.01 million
8/4/2022Q2 2022($0.28)($0.28)-($0.28)$12.25 million$5.54 million
5/9/2022Q1 2022($0.26)($0.32)($0.06)($0.32)$4.00 million$3.58 million    
3/14/2022Q4 2021($0.22)($0.25)($0.03)($0.25)$80.25 million$1.42 million    
11/4/2021Q3 2021($0.26)($0.30)($0.04)($0.27)$1.20 million$1.20 million    
8/8/2021Q2 2021($0.25)($0.24)+$0.01($0.24)$0.60 million$3.10 million    
5/5/2021Q1 2021($0.25)($0.24)+$0.01($0.24)$0.75 million$0.43 million  

Adaptimmune Therapeutics Earnings - Frequently Asked Questions

When is Adaptimmune Therapeutics's earnings date?

Adaptimmune Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Friday, May 10th, 2024 based off last year's report dates. Learn more on ADAP's earnings history.

Did Adaptimmune Therapeutics beat their earnings estimates last quarter?

In the previous quarter, Adaptimmune Therapeutics (NASDAQ:ADAP) missed the analysts' consensus estimate of ($0.12) by $0.12 with a reported earnings per share (EPS) of ($0.24). Learn more on analysts' earnings estimate vs. ADAP's actual earnings.

How much revenue does Adaptimmune Therapeutics generate each year?

Adaptimmune Therapeutics (NASDAQ:ADAP) has a recorded annual revenue of $60.28 million.

How much profit does Adaptimmune Therapeutics generate each year?

Adaptimmune Therapeutics (NASDAQ:ADAP) has a recorded net income of -$113.87 million. ADAP has generated -$0.55 earnings per share over the last four quarters.

What is Adaptimmune Therapeutics's EPS forecast for next year?

Adaptimmune Therapeutics's earnings are expected to grow from ($0.49) per share to ($0.48) per share in the next year.


More Earnings Resources from MarketBeat

This page (NASDAQ:ADAP) was last updated on 4/23/2024 by MarketBeat.com Staff

From Our Partners